Discloses adjustments reconciling IFRS results to Core results. Revenue was 911.6 billion yen (IFRS) \u2192 adjusted to 1,068.1 billion yen (Core cumulative), etc. Operating income was 429.8 billion yen (IFRS), adjusted to 536.1 billion yen cumulative. Outlook for Q4 onward is provided in a separate document; published exchange rates are used as the currency assumptions. Long-term plans and investment metrics are also presented.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-10-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4519-20261027-02.pdf","jir_short_summary":"Discloses adjustments reconciling IFRS results to Core results. Revenue was 911.6 billion yen (IFRS) \u2192 adjusted to 1,068.1 billion yen (Core cumulative), etc. Operating income was 429.8 billion yen (IFRS), adjusted to 536.1 billion yen cumulative. Outlook for Q4 onward is provided in a separate document; published exchange rates are used as the currency assumptions. Long-term plans and investment metrics are also presented.","jir_summary":"### Summary of Results\nChugai Pharmaceutical has disclosed adjustments reconciling IFRS results to Core results. Revenue on a cumulative IFRS basis was 911.6 billion yen, while the supplemental Core cumulative results increased to 1,068.1 billion yen. Operating income was 429.8 billion yen on an IFRS cumulative basis and expanded to 536.1 billion yen on a cumulative Core basis. Research and development expenses and selling, general and administrative expense trends are compared on a Core-results basis, and adjustments such as intangible asset amortization and impairments are described in detail.\n\n### Outlook and Financial Indicators\nCore results are presented as indicators adjusted for non-recurring items relative to IFRS results, with financial ratios such as ROIC and ROA provided. Exchange rates use the period average market rates stated in the materials. Long-term business investments and changes in R&D spending may affect the trajectory of Core indicators.","jir_financial_highlights":"Revenue: 9,116 (Cumulative IFRS results)\nRevenue: 10,681 (Cumulative Core results (supplemental))\nOperating income: 4,298 (Cumulative IFRS results)\nNet income: 3,056 (Cumulative IFRS results)\nCore EPS: 60.30 (Quarter\/Cumulative)","jir_category":"","jir_hashtags":"#ChugaiPharmaceutical, #EarningsSupplement, #IFRS, #CoreResults","jir_key_figures":"Revenue IFRS results: 9,116 (cumulative) \u2192 9,116 hundred million yen\nRevenue Core cumulative: 10,681 \u2192 10,681 hundred million yen\nOperating income IFRS cumulative: 5,361 \u2192 5,361 hundred million yen\nNet income IFRS cumulative: 3,847 \u2192 3,847 hundred million yen\nCore EPS: 60.30","jir_meta_title":"Chugai Pharmaceutical Co., Ltd. Q3 FY2026 Supplemental Financial Results | Disclosure of Differences Between Core and IFRS Results","jir_meta_description":"The supplemental materials for Chugai Pharmaceutical Co., Ltd.'s Q3 FY2026 consolidated results disclose adjustments between IFRS and Core results and present key metrics (revenue, operating income, net income), along with currency assumptions and outlook.","jir_og_title":"Chugai Pharmaceutical Announces Q3 Supplemental Results | Differences Between IFRS and Core Results","jir_og_description":"Chugai Pharmaceutical discloses adjustments reconciling IFRS results and Core results for Q3 FY2026, detailing revenue and profit trends and core metrics.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-134985","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n